GlassScriptPhysician profile
Katrina Mccourt
NPI 1063810711
$1,300.67
in general payments reported to CMS, 2019-2025
25 companies · $276 in 2025
The $276 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $283 · 2023: $654 · 2024: $87.33 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,017.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $216.30 | 2023-2024 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $200.51 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Abbvie INC. | $119.40 | 2023-2025 | |
| Alkermes, INC. | $109.01 | 2022-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $70.28 | 2022-2025 | Ingrezza |
| Corium, LLC | $64.93 | 2023 | Azstarys |
| Abbott Laboratories | $64.39 | 2022-2023 | Freestyle Libre 2 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.28 | 2023-2025 | Caplyta |
| Novo Nordisk INC | $60.45 | 2022-2023 | Wegovy |
| Lilly USA, LLC | $56.10 | 2022 | |
| Noven Therapeutics, LLC | $37.94 | 2023 | Xelstrym |
| Lundbeck LLC | $35.33 | 2023-2025 | Rexulti |
| Neos Therapeutics, LP | $26.73 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.89 | 2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $17.50 | 2025 | Austedo Xr |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $16.80 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.67 | 2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $15.49 | 2022 | |
| Vanda Pharmaceuticals INC. | $15.47 | 2023 | Hetlioz, Fanapt |
| Tris Pharma INC | $14.70 | 2023 | Dyanavel Xr |
| Sanofi-Aventis U.S. LLC | $13.91 | 2022 | |
| Merck Sharp & Dohme LLC | $12.95 | 2023 | Belsomra |
| Supernus Pharmaceuticals, INC. | $12.80 | 2023 | Qelbree |
| Avion Pharmaceuticals | $12.78 | 2023 | Methylphenidate Hydrochloride |
| Dexcom, INC. | $12.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katrina Mccourt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.